KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNTech SE (BNTX) Raw Materials (2018 - 2021)

BioNTech SE's Raw Materials history spans 4 years, with the latest figure at $284.0 million for Q4 2021.

  • On a quarterly basis, Raw Materials rose 437.78% to $284.0 million in Q4 2021 year-over-year; TTM through Dec 2021 was $284.0 million, a 437.78% increase, with the full-year FY2021 number at $284.0 million, up 437.78% from a year prior.
  • Raw Materials hit $284.0 million in Q4 2021 for BioNTech SE, up from $203.9 million in the prior quarter.
  • Over the last five years, Raw Materials for BNTX hit a ceiling of $284.0 million in Q4 2021 and a floor of $5.1 million in Q4 2018.
  • Historically, Raw Materials has averaged $111.0 million across 4 years, with a median of $52.8 million in 2020.
  • Biggest five-year swings in Raw Materials: skyrocketed 77.72% in 2019 and later skyrocketed 481.86% in 2020.
  • Tracing BNTX's Raw Materials over 4 years: stood at $5.1 million in 2018, then skyrocketed by 77.72% to $9.1 million in 2019, then skyrocketed by 481.86% to $52.8 million in 2020, then surged by 437.78% to $284.0 million in 2021.
  • Business Quant data shows Raw Materials for BNTX at $284.0 million in Q4 2021, $203.9 million in Q2 2021, and $52.8 million in Q4 2020.